---
title: "12 Health Care Stocks Moving In Thursday's After-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290249678.md"
description: "During Thursday's after-market session, several healthcare stocks experienced significant volatility. Tenon Medical surged 168.9% to $0.94, while Azitra rose 20.44%. Other gainers included Impact BioMedical, Nutriband, Pulmatrix, and Agape ATP. Conversely, PAVmed dropped 15.5%, Cryo-Cell International fell 13.97%, and Cellectar Biosciences declined 8.97%. Other losers were Genprex, Aspire Biopharma Holdings, and OS Therapies."
datetime: "2026-06-18T21:06:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290249678.md)
  - [en](https://longbridge.com/en/news/290249678.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290249678.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Thursday's After-Market Session

### Gainers

-   **Tenon Medical** (NASDAQ:TNON) stock increased by 168.9% to $0.94 during Thursday's after-market session. The market value of their outstanding shares is at $6.9 million.
-   **Azitra** (AMEX:AZTR) stock moved upwards by 20.44% to $0.21. The company's market cap stands at $3.2 million.
-   **Impact BioMedical** (AMEX:IBO) shares moved upwards by 13.18% to $0.57. The company's market cap stands at $62.2 million.
-   **Nutriband** (NASDAQ:NTRB) stock rose 12.77% to $3.27. The company's market cap stands at $37.1 million.
-   **Pulmatrix** (NASDAQ:PULM) shares rose 11.64% to $1.63. The company's market cap stands at $5.4 million.
-   **Agape ATP** (NASDAQ:ATPC) stock rose 9.02% to $4.23. The company's market cap stands at $2.7 million.

### Losers

-   **PAVmed** (NASDAQ:PAVM) stock declined by 15.5% to $4.36 during Thursday's after-market session. The market value of their outstanding shares is at $35.7 million.
-   **Cryo-Cell International** (AMEX:CCEL) shares decreased by 13.97% to $3.48. The market value of their outstanding shares is at $28.4 million.
-   **Cellectar Biosciences** (NASDAQ:CLRB) shares decreased by 8.97% to $2.54. The market value of their outstanding shares is at $19.8 million.
-   **Genprex** (NASDAQ:GNPX) shares decreased by 8.81% to $0.54. The company's market cap stands at $5.2 million.
-   **Aspire Biopharma Holdings** (NASDAQ:ASBP) shares fell 7.3% to $6.1. The company's market cap stands at $8.2 million.
-   **OS Therapies** (AMEX:OSTX) stock declined by 7.26% to $1.79. The company's market cap stands at $76.6 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [NTRB.US](https://longbridge.com/en/quote/NTRB.US.md)
- [IBO.US](https://longbridge.com/en/quote/IBO.US.md)
- [ATPC.US](https://longbridge.com/en/quote/ATPC.US.md)
- [GNPX.US](https://longbridge.com/en/quote/GNPX.US.md)
- [PULM.US](https://longbridge.com/en/quote/PULM.US.md)
- [PAVM.US](https://longbridge.com/en/quote/PAVM.US.md)
- [CLRB.US](https://longbridge.com/en/quote/CLRB.US.md)
- [ASBP.US](https://longbridge.com/en/quote/ASBP.US.md)
- [CCEL.US](https://longbridge.com/en/quote/CCEL.US.md)
- [OSTX.US](https://longbridge.com/en/quote/OSTX.US.md)
- [TNON.US](https://longbridge.com/en/quote/TNON.US.md)
- [AZTR.US](https://longbridge.com/en/quote/AZTR.US.md)
- [TNONW.US](https://longbridge.com/en/quote/TNONW.US.md)
- [NTRBW.US](https://longbridge.com/en/quote/NTRBW.US.md)
- [PAVMZ.US](https://longbridge.com/en/quote/PAVMZ.US.md)
- [ASBPW.US](https://longbridge.com/en/quote/ASBPW.US.md)

## Related News & Research

- [PAVmed Maintained at Buy as Analyst Sees Long-Term Growth Upside; $16 Price Target Reaffirmed](https://longbridge.com/en/news/296006890.md)
- [CLRB: Lead radioconjugate shows strong efficacy in WM, with broad pipeline and solid financials](https://longbridge.com/en/news/296262059.md)
- [Tenon Medical completes $3M private warrant financing](https://longbridge.com/en/news/297555992.md)
- [OS Therapies wins FDA Type C meeting to review 2.5-year survival data for OST-HER2 Phase 2b osteosarcoma trial](https://longbridge.com/en/news/295800970.md)
- [Genprex signs CDMO deal to scale up manufacturing for diabetes gene therapy program](https://longbridge.com/en/news/296218198.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**